04:31 PM EDT, 03/12/2026 (MT Newswires) -- Nektar Therapeutics ( NKTR ) reported a Q4 loss late Thursday of $1.78 per diluted share, swinging from earnings of $0.52 a year earlier.

Analysts surveyed by FactSet expected a loss of $2.47.

Revenue for the three months ended Dec. 31 was $21.8 million, down from $29.2 million a year earlier.

Analysts polled by FactSet expected $10.2 million.